N,N-dimethyl-4-oxobutanamide | 288569-59-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N,N-dimethyl-4-oxobutanamide
• CAS: 288569-59-5
• 化学式: C₆H₁₁NO₂
• mdl: MFCD18827204
• 分子量: 129.159
• InChiKey: OXQZTLTUQUOYQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-4-oxobutanamide 在 palladium diacetate 、 溶剂黄146 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 tert-butyl (endo)-5-(6-bromo-7-chloro-8-(2-cyanovinyl)-2-(3-(dimethylamino)-3-oxopropyl)-4-(3-(dimethylamino)azetidin-1-yl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-azabicyclo[2.1.1]hexane-2-carboxylate
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
  [FR] COMPOSÉS TRICYCLIQUES UTILES EN TANT QU'INHIBITEURS DE KRAS

  摘要：

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

  公开号：

  WO2023287896A1
• 作为产物：
  描述：

  4-hydroxy-N,N-dimethylbutanamide 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N,N-dimethyl-4-oxobutanamide
  参考文献：
  名称：

  A trialkylstannane-mediated approach to acyloin products

  摘要：

  DOI：

  10.1021/jo00223a051

文献信息

• Cyclic substituted fused pyrrolocarbazoles and isoindolones
  申请人：Cephalon, Inc.

  公开号：US20040186157A1

  公开（公告）日：2004-09-23

  The present invention is directed to cyclic substituted fused pyrrolocarbazoles and isoindolones. The invention also is directed to methods for making and using the cyclic substituted fused pyrrolocarbazoles and isoindolones.

  本发明涉及环替代融合吡咯咯咯吡咯咯咯和异吲哚酮。该发明还涉及制备和使用环替代融合吡咯咯咯吡咯咯咯和异吲哚酮的方法。
• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• [EN] CYCLOHEXYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] DERIVES DE LA CYCLOHEXYLALANINE UTILISES COMME INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE-IV POUR LE TRAITEMENT OU LA PREVENTION DES DIABETES
  申请人：MERCK & CO INC

  公开号：WO2005116029A1

  公开（公告）日：2005-12-08

  The present invention is directed to novel cyclohexylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及新颖的环己基丙氨酸衍生物，这些衍生物是二肽基肽酶-IV酶（'DP-IV抑制剂'）的抑制剂，并且在治疗或预防涉及二肽基肽酶-IV酶的疾病中具有用处，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及二肽基肽酶-IV酶的这类疾病中使用这些化合物和组合物。
• Regioselective and Enantioselective Hydroformylation of Dialkylacrylamides
  作者：Gary M. Noonan、David Newton、Christopher J. Cobley、Andrés Suárez、Antonio Pizzano、Matthew L. Clarke

  DOI：10.1002/adsc.200900871

  日期：——

  possible, provided steps are taken to minimise racemisation of the aldehyde products, and this work demonstrates the effect of various conditions and variables on racemisation. Using the Landis diazaphospholane ligands up to 68% ee can be realised under very mild conditions. Other dialkylacrylamides were also hydroformylated under mild conditions giving similar or better enantioselectivities, including

  二甲基丙烯酰胺可以以很高的化学和区域选择性加氢甲酰化。该底物的不对称加氢甲酰化是可能的，只要采取步骤使醛产物的外消旋化最小化即可，并且这项工作证明了各种条件和变量对外消旋化的影响。在非常温和的条件下，使用Landis二氮磷杂环戊烷配体可以达到ee的68％。其他二烷基丙烯酰胺也可在温和条件下加氢甲酰化，得到相似或更好的对映选择性，包​​括丙烯酸的Weinreb酰胺（71％ee），以及二乙基丙烯酰胺的不对称加氢甲酰化生成手性醛，ee最高可达82％。
• New Tetraphosphorus Ligands for Highly Linear Selective Hydroformylation of Allyl and Vinyl Derivatives
  作者：Chaoxian Cai、Shichao Yu、Bonan Cao、Xumu Zhang

  DOI：10.1002/chem.201201396

  日期：2012.8.6

  New tetraphosphorus ligands have been developed and applied in the rhodium‐catalyzed regioselective hydroformylation of a variety of functionalized allyl and vinyl derivatives. Remarkably high linear selectivity was obtained by these tetraphosphorus ligands. The ligand that bears strong electron‐withdrawing 2,4‐difluorophenyl groups is the most effective one in affording linear aldehydes. The Rh/tetraphosphorus

  已开发出新的四磷配体，并将其用于铑催化的多种功能化的烯丙基和乙烯基衍生物的区域选择性加氢甲酰化反应。这些四磷配体获得了显着高的线性选择性。带有强吸电子的2,4-二氟苯基的配体是提供线性醛最有效的配体。Rh /四磷配体催化剂非常有效地从官能化的烯丙基衍生物生产线性醛，所述烯丙基衍生物具有直接邻近于烯丙基的杂原子或芳族基团。对于乙烯基衍生物，该配体对丙烯酸衍生物，苯乙烯，乙烯基吡啶和乙烯基邻苯二甲酰亚胺具有高度线性的选择性。对于苯乙烯和烯丙基氰化物的加氢甲酰化，分别获得26：1和10：1的线性与支链比。